What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It?

@inproceedings{Kemp2010WhatIC,
  title={What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It?},
  author={Aaron S. Kemp and Nina Schooler and Amir H. Kalali and Larry D. Alphs and Ravi R. Anand and George A Awad and Michael Davidson and Sanjay Dub{\'e} and Larry Ereshefsky and Georges M Gharabawi and Andrew C. Leon and J P L{\'e}pine and Steven G. Potkin and An M. Vermeulen},
  booktitle={Schizophrenia bulletin},
  year={2010}
}
On September 18, 2007, a collaborative session between the International Society for CNS Clinical Trials and Methodology and the International Society for CNS Drug Development was held in Brussels, Belgium. Both groups, with membership from industry, academia, and governmental and nongovernmental agencies, have been formed to address scientific, clinical, regulatory, and methodological challenges in the development of central nervous system therapeutic agents. The focus of this joint session… CONTINUE READING